Arming oncolytic viruses to leverage antitumor immunity

Expert Opinion on Biological Therapy

Volumn 15, Issue 7, 2015, Pages 959-971

  De Gruijl, Tanja D ^a   Janssen, Axel B ^a   Van Beusechem, Victor W ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antitumor immunity; Immune suppression; Immunotherapy; Oncolytic viruses; Tumor microenvironment; Virotherapy

Indexed keywords

CYTOKINE; ONCOLYTIC VIRUS; RECEPTOR; CANCER VACCINE; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL DEATH; CROSS PRESENTATION; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; MALIGNANT NEOPLASTIC DISEASE; ONCOLYTIC VIROTHERAPY; REVIEW; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; CYTOTOXIC T LYMPHOCYTE; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASMS;

ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOKINES; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MICROENVIRONMENT;

EID: 84931060884     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1044433     Document Type: Review

References (96)

1. Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res 2014;2:295-300
2. Gujar SA, Lee PWK. Oncolytic virusmediated reversal of impaired tumor antigen presentation. Front Oncol 2014;4:77
3. Lichty BD, Breitbach CJ, Stojdl DF, et al. Going viral with cancer immunotherapy. Nat Rev Cancer 2014;14:559-67
4. Parato KA, Senger D, Forsyth PA, et al. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005;5:965-76
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74
6. Moehler M, Goepfert K, Heinrich B, et al. Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1. Front Oncol 2014;4:92
7. Bartlett DL, Liu Z, Sathaiah M, et al. Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer 2013;12:1-16
8. Devaud JC, John LB, Westwood JA, et al. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2013;2:e25961
9. Guo ZS, Liu Z, Bartlett DL. Oncolytic Immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol 2014;4:74
10. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012;21:309-22
11. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci 2012;125:5591-6
12. Sounni NE, Noel A. Targeting the tumor microenvironment for cancer therapy. Clin Chem 2013;59:85-93
13. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012;196:395-406
14. Bronte V, Serafini P, Mazzoni A, et al. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 2003;24:301-5
15. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52-67
16. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974-7
17. Brower V. Approval of provenge seen as first step for cancer treatment vaccines. J Natl Cancer Inst 2010;102:1108-10
18. DeFrancesco L. Landmark approval for Dendreon's cancer vaccine. Nat Biotechnol 2010;28:531-2
19. Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol 2015;33C:23-35
20. Pol J, Bloy N, Obrist F, et al. Trial Watch: Oncolytic viruses in cancer therapy. Oncoimmunology 2014;3:e28694
21. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2014;30:1-29
22. Vacchelli E, Eggermont A, Sautès-Fridman C, et al. Trial Watch: Oncolytic viruses for cancer therapy. Oncoimmunology 2013;6:e24612
23. van Rooij N, van Buuren MM, Philips D, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013;31:e439-42
24. Linnemann C, van Buuren MM, Bies L, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med 2015;21:81-5
25. Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014;344:641-5
26. Robbins PF, Lu YC, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013;19:747-52 •• Seminal study showing that melanoma-infiltrating T cells are in large part directed against neo-epitopes derived from tumor-specific mutations.
27. Zamarin D, Holmgaard RB, Subudhi SK, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 2014;6:226ra32 •• Pre-clinical study showing that local intratumoral delivery of OVs combined with systemic anti-CTLA-4 treatment results in a systemic antitumor immune response and tumor protection in a weakly immunogenic melanoma tumor model.
28. Hallden G, Hill R, Wang Y, et al. Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol Ther 2003;8:412-24
29. Bernt KM, Ni S, Tieu AT, et al. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Cancer Res 2005;65:4343-52
30. Robinson M, Li B, Ge Y, et al. Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors. J Virol 2009;83:3450-62
31. Edukulla R, Ramakrishna E, Woller N, et al. Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. Cancer Res 2009;69:1448-58
32. Lapteva N, Aldrich M, Rollins L, et al. Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther 2009;17:1626-36
33. Lapteva N, Aldrich M, Weksberg D, et al. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J Immunother 2009;32:145-56
34. Rodriguez-Rocha H, Gomez-Gutierrez JG, Garcia-Garcia A, et al. Adenoviruses induce autophagy to promote virus replication and oncolysis. Virology 2011;416:9-15
35. Jiang H, White EJ, Ríos-Vicil CI, et al. Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity. J Virol 2011;85:4720-9
36. Li Y, Wang LX, Yang G, et al. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res 2008;68:6889-95
37. Fukuhara H, Ino Y, Kuroda T, et al. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res 2005;65:10663-8
38. Nastala CL, Edington HD, Mckinney TC, et al. Recombinant IL-12 administration induces tumor regression in association with IFNy production. J Immunol 1994;4:1697-706
39. LaRocca CJ, Han J, Gavrikova T, et al. Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer. Surgery 2015. [Epub ahead of print]
40. Hirvinen M, Rajecki M, Kapanen M, et al. Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus. Hum Gene Ther 2015. [Epub ahead of print]
41. Grote D, Cattaneo R, Fielding AK. Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res 2003;63:6463-8
42. Parviainen S, Ahonen M, Diaconu I, et al. GMCSF-armed vaccinia virus induces an antitumor immune response. Int J Cancer 2015;136:1065-72
43. Carew JF, Kooby DA, Halterman MW, et al. A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes. Mol Ther 2001;4:250-6
44. Derubertis BG, Stiles BM, Bhargava A, et al. Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms. Cancer Gene Ther 2007;14:590-7
45. Murakami N, Riella LV. Co-inhibitory pathways and their importance in immune regulation. Transplantation 2014;98:3-14
46. Lindenberg JJ, Fehres CM, van Cruijsen H, et al. Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity. Immunotherapy 2011;3:77-96
47. Kaufman HL, Ruby CE, Hughes T, et al. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer 2014;13:2-11
48. Hemminki O, Parviainen S, Juhila J, et al. Immunological data from cancer patients treated with Ad5/3 E2F D24 GMCSF suggests utility for tumor immunotherapy. Oncotarget 2015;6:4467-81
49. Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013;19:329-36
50. Kim MK, Breitbach CJ, Moon A, et al. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci Transl Med 2013;5:185ra63
51. Andtbacka RH, Collichio FA, Amatruda T, et al. Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704). J Immunother Cancer 2014;2(Suppl 3):P263
52. Lee YS, Kim JH, Choi KJ, et al. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res 2006;12:5859-68
53. Huang JH, Zhang SN, Choi KJ, et al. Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol Ther 2010;18:264-74
54. Terada K, Wakimoto H, Tyminski E, et al. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther 2006;13:705-14
55. Galivo F, Diaz RM, Thanarajasingam U, et al. Interference of CD40L-mediated tumor immunotherapy. Hum Gene Ther 2010;21:439-50
56. Li J, O'Malley M, Urban J, et al. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther 2011;19:650-7
57. Li J, O'Malley M, Sampath P, et al. Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity. Neoplasia 2012;14:1115-21
58. Fu X, Rivera A, Tao L, et al. An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites. Oncotarget 2015;6:902-14
59. Basu S, Srivastava PK. Heat shock proteins: the fountainhead of innate and adaptive immune responses. Cell Stress Chaperones 2000;5:443
60. Benencia F, Courrèges MC, Fraser NW, et al. Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biol Ther 2008;7:1194-205
61. Li JL, Liu HL, Zhang XR, et al. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Ther 2009;16:376-82
62. Donnelly OG, Errington-Mais F, Steele L, et al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther 2013;20:7-15
63. Guo ZS, Naik A, O'Malley ME, et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res 2005;65:9991-8
64. Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun 2005;73:1907-16
65. Gujar SA, Marcato P, Pan D, et al. Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity. Mol Cancer Ther 2010;9:2924-33
66. Gujar S, Dielschneider R, Clements D, et al. Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation. Mol Ther 2013;21:338-47
67. Le Bon A, Etchart N, Rossmann C, et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003;4:1009-15
68. Sluijter B, van den Hout MF, Koster BD, et al. Arming the melanoma SLN through local administration of CpG-B and GM-CSF: recruitment and activation of BDCA3/CD141+ DC and enhanced cross-presentation. Cancer Immunol Res 2015. [Epub ahead of print]
69. Ressing ME, Luteijn RD, Horst D, et al. Viral interference with antigen presentation: trapping TAP. Mol Immunol 2013;55:139-42
70. Leveille S, Goulet ML, Lichty BD, et al. Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation. J Virol 2011;85:12160-9
71. Dias JD, Hemminki O, Diaconu I, et al. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther 2012;19:988-98
72. Blank C, Kuball J, Voelkl S, et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006;119:317-27
73. Bauzon M, Hermiston T. Armed therapeutic viruses-a disruptive therapy on the horizon of cancer immunotherapy. Front Immunol 2014;5:74
74. Engeland CE, Grossardt C, Veinalde R, et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther 2014;22:1949-59
75. Ott P, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013;19:5300-9
76. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005;23:741-50
77. Frentzen A, Yu YA, Chen N, et al. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci USA 2009;106:12915-20
78. Chakravarty R, Goel S, Cai W. Nanobody: the "magic bullet" for molecular imaging? Theranostics 2014;4:386-98
79. Choi BD, Cai M, Bigner DD, et al. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther 2011;11:843-53
80. Lameris R, de Bruin RC, Schneiders FL, et al. Bispecific antibody platforms for cancer immunotherapy. Crit Rev Oncol Hematol 2014;92:153-65
81. Yokota T, Milenic DE, Whitlow M, et al. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402-8
82. Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011;331:1612-16
83. Gottschalk S, Rooney CM. Harnessing the immune system to potentiate oncolytics. Mol Ther 2014;22:239-40
84. Iwahori K, Kakarla S, Velasquez MP, et al. Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol Ther 2015;23:171-8
85. Yu F, Wang X, Guo ZS, et al. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther 2014;22:102-11
86. Dreier T, Baeuerle PA, Fichtner I, et al. T Cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. J Immunol 2003;170:4397-402
87. Albelda SM, Thorne SH. Giving oncolytic vaccinia virus more BiTE. Mol Ther 2014;22:6-8
88. Harrop R, John J, Carroll MW. Recombinant viral vectors: cancer vaccines. Adv Drug Deliv Rev 2006;58:931-47
89. Raki M, Sarkioja M, Escutenaire S, et al. Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients. J Gene Med 2011;13:253-61
90. de Gruijl TD, van de Ven R. Adenovirus-based immunotherapy of cancer: promises to keep. Adv Cancer Res 2012;115:147-220
91. Kelderman S, Schumacher TN, Haanen JB. Acquired and intrinsic resistance in cancer immunotherapy. Mol Oncol 2014;8:1132-9
92. Walther W, Schlag PM. Current status of gene therapy for cancer. Curr Opin Oncol 2013;25:659-64
93. Kloos A, Woller N, Guerlevik E, et al. PolySia-specific retargeting of oncolytic viruses triggers tumor-specific immune responses and facilitates therapy of disseminated lung cancer. Cancer Immunol Res 2015. [Epub ahead of print]
94. van Erp EA, Kaliberova LN, Kaliberov SA, Curiel DT. Retargeted oncolytic adenovirus displaying a single variable domain of camelid heavy-chain-only antibody in a fiber protein. Mol Ther-Oncolytics 2015;2:15001
95. Lindenberg JJ, van de Ven R, Lougheed SM, et al. Functional characterization of a STAT3-dependent dendritic cell-derived CD14(+) cell population arising upon IL-10-driven maturation. Oncoimmunology 2013;2:e23837
96. Du T, Shi G, Li YM, et al. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers. Cancer Gene Ther 2014;21:340-8